JEROME B. ZELDIS - 02 Jan 2026 Form 4 Insider Report for PTC THERAPEUTICS, INC. (PTCT)

Role
Director
Signature
/s/ Avraham S. Adler, Attorney-in-Fact
Issuer symbol
PTCT
Transactions as of
02 Jan 2026
Net transactions value
$0
Form type
4
Filing time
06 Jan 2026, 17:20:21 UTC
Previous filing
27 Jun 2025
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
ZELDIS JEROME B Director C/O PTC THERAPEUTICS, INC., 500 WARREN CORPORATE CENTER DRIVE, WARREN /s/ Avraham S. Adler, Attorney-in-Fact 06 Jan 2026 0001433982

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction PTCT Common Stock Award $0 +4,000 +22% $0.000000 22,500 02 Jan 2026 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction PTCT Stock Option (Right to Buy) Award $0 +3,475 $0.000000 3,475 02 Jan 2026 Common Stock 3,475 $76.74 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Restricted stock units granted on January 2, 2026 that vest over one year, with five-twelfths (5/12) of the shares underlying the RSUs vesting on June 2, 2026 and the remaining seven-twelfths (7/12) of the original shares underlying the RSUs vesting on January 2, 2027. The Reporting Person has elected to defer receipt of all vested shares until the earliest to occur of (i) four years from the date of grant and (ii) the earliest to occur of (a) the date that is six months following separation of service from the Issuer, (b) a change in control event and (c) death.
F2 This option was granted on January 2, 2026 and vests over one year in twelve equal monthly installments, commencing on February 2, 2026.